GRI918013
GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC50=31.42 nM, Ki=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 313685-55-1
- Formule: C17H15Cl2FN2O4S
- Masse moléculaire:433.28
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
Autotaxin |
GRI918013 (10 µM; 3 h) competitively inhibits ATX-mediated FS-3 hydrolysis (IC50=31.42 nM; Ki=12.98 nM), but does not inhibit the hydrolysis of the phosphodiesterase (PDE) substrate pNP-TMP, and has no effect on NPP6, NPP7, or LPA and S1P receptors[1].
GRI918013 (10 µM; 2 h) inhibits the hydrolysis of four substrates, LPC 14:0, LPC 16:0, LPC 18:0, and LPC 18:1, mediated by ATX, with inhibition rates of 41.0%, 55.4%, 43.6%, and 51.8%, respectively[1].
GRI918013 dose-dependently inhibits ATX-dependent A2058 cell invasion (IC50 = 118.79 nM, 16 h)[1].
GRI918013 has reduced inhibitory potency on ATXF275A mutant (IC50 >10 μM vs ATXWT 3.0 μM) and maintains potency on ATXY83A mutant (IC50=0.15 μM)[1].
GRI918013 (10 µM; 4 h) inhibits ATX-mediated ADMAN-LPC hydrolysis by 89.0%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A2058 human melanoma cells
-
Concentration:0.01, 0.1, 1, 10 μM
-
Incubation Time:16 hours
-
Result:Dose-dependently inhibited ATX-dependent A2058 cell invasion with an IC50 of 118.79 nM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (female, 8–12 weeks old)[1]
-
Dosage:30 µg/mouse
-
Administration:i.p.; daily; 10 days
-
Result:Significantly reduced the number of lung metastatic nodules when administered 1 day before or 1 day after tumor cell inoculation compared to vehicle-treated controls.
Chemical Information
-
CAS No. 313685-55-1
-
Masse moléculaire 433.28
-
Formule C17H15Cl2FN2O4S
-
SMILES
O=C(NC=1C=CC=C(F)C1)C=2C=C(C(Cl)=CC2Cl)S(=O)(=O)N3CCOCC3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GRI918013 Related Classifications
HY-119601 Related Classifications
Powered by Bioz